Definitive Healthcare 8-K: Financials & Officer Changes Reported

TL;DR

**Definitive Healthcare just filed an 8-K hinting at financial updates and leadership changes.**

AI Summary

Definitive Healthcare Corp. filed an 8-K on January 16, 2024, reporting events that occurred on January 12, 2024. The filing indicates that the company is reporting on 'Results of Operations and Financial Condition' and 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'. This matters to investors because it signals potential changes in the company's financial performance or leadership, which could impact future stock value and strategic direction.

Why It Matters

This filing signals potential shifts in Definitive Healthcare's financial health or executive team, which are critical factors for investors assessing the company's stability and growth prospects.

Risk Assessment

Risk Level: medium — The filing mentions 'Results of Operations and Financial Condition' and 'Departure of Directors or Certain Officers', which could indicate either positive or negative developments, creating uncertainty.

Analyst Insight

A smart investor would monitor Definitive Healthcare's subsequent filings closely for specific details on financial performance and any executive changes, as these will clarify the impact of the events reported on January 12, 2024.

Key Players & Entities

• Definitive Healthcare Corp. (company) — the registrant filing the 8-K
• January 12, 2024 (date) — date of the earliest event reported
• January 16, 2024 (date) — date the 8-K was filed
• 001-40815 (other) — Commission File Number
• Delaware (other) — State of incorporation for Definitive Healthcare Corp.

Forward-Looking Statements

• Definitive Healthcare Corp. will release detailed financial results for the period ending December 31, 2023, in an upcoming filing. (Definitive Healthcare Corp.) — high confidence, target: Q1 2024
• The company will announce specific changes to its executive leadership or board of directors. (Definitive Healthcare Corp.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — which registered Class A Common Stock, $0.001 par value DH The Nasdaq Stock Marke
• $15,000 — f 15 months) and to reimburse him up to $15,000 for legal fees incurred by him in conne

Filing Documents

• d683059d8k.htm (8-K) — 29KB
• d683059dex101.htm (EX-10.1) — 67KB
• d683059dex991.htm (EX-99.1) — 16KB
• 0001193125-24-008562.txt ( ) — 257KB
• dh-20240112.xsd (EX-101.SCH) — 3KB
• dh-20240112_lab.xml (EX-101.LAB) — 18KB
• dh-20240112_pre.xml (EX-101.PRE) — 11KB
• d683059d8k_htm.xml (XML) — 3KB

02

Item 2.02 Results of Operations and Financial Condition On January 16, 2024, Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") issued a press release announcing the management changes described in Item 5.02 below and its reaffirmation of previously announced guidance for the quarter ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Item 2.02 on this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Separation of Chief Executive Officer On January 16, 2024, the Company announced that Robert Musslewhite has stepped down as the Company's Chief Executive Officer and as a member of the Company's Board of Directors, effective January 16, 2024 (the "Separation Date"). Mr. Musslewhite's departure constitutes a termination of employment without "cause" for purposes of any employment, equity compensation or benefit agreement, plan or arrangement of the Company and its subsidiaries to which Mr. Musslewhite is a party or otherwise participates; provided, however, that pursuant to a separation agreement and release of claims agreement dated January 12, 2024 (the "Separation Agreement"), the Company has agreed to credit Mr. Musslewhite with an additional three months of accelerated vesting with respect to his outstanding time-based equity awards (for a total of 15 months) and to reimburse him up to $15,000 for legal fees incurred by him in connection with the Separation Agreement. A copy of the Separation Agreement is attached as Exhibit 10.1 to this Current Report on Form 8-K. Appointment of Interim Chief Executive Officer On January 12, 2024, the Company's Board of Directors appointed Jason Krantz, the Company's founder and Executive Chairman, as Interim Chief Executive Officer, effective January 16, 2024. Mr. Krantz, age 50, has served as Executive Chairman of the Board of Directors of the Company since August 2022, having previously served as Chief Executive Officer and director since founding the Company in February 2011. Prior to founding Definitive Healthcare, Mr. Krantz founded and served as CEO of Infinata, a SaaS based provider of intelligence to the pharmaceutical industry under the brand BioPharm Insight, from 1999 to 2007 until the company was sold to Pearson Media Group. In addition, Mr. Kran

Financial Statements and Exhibits

Financial Statements and Exhibits. 10.1 Separation Agreement and Release of Claims, dated January 12, 2024, by and between the Company and Robert Musslewhite 99.1 Press Release dated January 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DEFINITIVE HEALTHCARE CORP. January 16, 2024 By: /s/ Richard Booth Richard Booth Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR